Актуальность

rehab

Реабилитология

Journal of Medical Rehabilitation

2949-58732949-5881

IRBIS LLC

10.17749/2949-5873/rehabil.2024.9

rehab-20

Research Article

ОБЗОРНЫЕ СТАТЬИ

REVIEW ARTICLES

Перспективные биомаркеры нарушения проницаемости гематоэнцефалического барьера в реабилитации детей с перинатальным гипоксическиишемическим поражением центральной нервной системы

Promising biomarkers of blood-brain barrier permeability impairment in rehabilitation of infants with perinatal hypoxic-ischemic central nervous system injury

https://orcid.org/0000-0001-9212-3865

Александров

А. Г.

Aleksandrov

A. G.

Александров Андрей Георгиевич - к.б.н. Scopus Author ID: 57211350219.

Ул. Садовая-Триумфальная, д. 4/10, Москва 127006; ул. Быкова, д. 84Б, Ленинградская обл., Всеволожский р-н, Колтушское с/п, с. Павлово 188680

Andrey G. Aleksandrov - PhD. Scopus Author ID: 57211350219.

4/10 Sadovaya-Triumfalnaya Str., Moscow 127006; 84B Bykov Str., Leningrad Region, Vsevolozhsk District, Koltushskoye Rural Settlement, Pavlovo 188680

andrey.alexandrov@ipsom.ru

https://orcid.org/0000-0001-5849-5585

Петренко

Д. А.

Petrenko

D. A.

Петренко Дарья Андреевна

Ул. Трубецкая, д. 8/2, Москва 119048

Daria A. Petrenko

8/2 Trubetskaya Str., Moscow 119048

Институт Превентивной и Социальной Медицины; Центр доклинических исследований «Фармакоген»РоссияInstitute for Preventive and Social Medicine; “Pharmacogen” Center for Preclinical ResearchRussian Federation

Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет им. И.М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияSechenov UniversityRussian Federation

2024

10092024

22207215

2024

Александров А.Г., Петренко Д.А.

Aleksandrov A.G., Petrenko D.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.rehabilitology.com/jour/article/view/20

Актуальность

Актуальность. Диагностика, лечение и реабилитация новорожденных с повреждением тканей центральной нервной системы (ЦНС) являются актуальной проблемой современного медицинского сообщества. Ранняя диагностика гипоксически-ишемических нарушений ЦНС – ключевой элемент в стратегии ведения новорожденных с выявленной асфиксией. Поиск чувствительных и специфичных диагностических инструментов позволит улучшить прогноз исхода заболевания и эффективность проводимой реабилитации.

Цель

Цель: выделить перспективные сывороточные биомаркеры повреждения тканей головного мозга для скрининга и мониторинга состояния новорожденных.

Материал и методы

Материал и методы. Поиск публикаций проведен автоматически в научных базах данных PubMed/MEDLINE, Google Scholar, ScienceDirect и электронной библиотеке eLibrary, а также вручную в поисковых системах Яндекс, Google. Последующий отбор исследований выполнен с учетом рекомендаций PRISMA. Из обнаруженных 3778 публикаций в обзор включены 52.

Результаты

Результаты. Представлены перспективные биомаркеры повреждения головного мозга, определяемые в сыворотке крови у новорожденных: дипептидилпептидаза-4, ряд цитокинов, нейронспецифичная енолаза (НСЕ), бутилкарнитин, кальций-связывающий белок B S100 (S100B), F2-изопростаны, ядросодержащие эритроциты, а также некоторые другие биомаркеры, изменение уровня которых коррелировало с выраженностью нарушения тканей ЦНС.

Заключение

Заключение. Дисфункция гематоэнцефалического барьера вызывает появление в сыворотке крови высокоспецифичных белков повреждения нейронов и глии, в частности S100B и НСЕ, которые можно определить как биомаркеры. Необходимо расширять доказательную базу и валидацию использования указанных биомаркеров с целью последующего внедрения в клинические рекомендаций по ведению пациентов с повреждением тканей ЦНС в раннем постнатальном периоде для своевременной диагностики и коррекции реабилитационных мероприятий.

Background

Background. Diagnostics, treatment and rehabilitation of newborns with injury of the central nervous system (CNS) tissues are one of the pressing problems of contemporary medical community. Early diagnostics of hypoxic-ischemic damage to CNS tissues is a key element in the strategy of supporting newborns with asphyxia. The search for sensitive and specific diagnostic tools will improve the prognosis of disease outcome and the effectiveness of rehabilitation.

Objective

Objective: to identify promising serum biomarkers of brain tissue damage for screening and monitoring in neonates.

Material and methods

Material and methods. The search for publications was carried out automatically in scientific databases (PubMed/MEDLINE, Google Scholar, ScienceDirect) and electronic library (eLibrary) as well as manually in search engines (Yandex, Google). The subsequent selection of articles was carried out according to PRISMA recommendations. Of 3778 publications found, 52 were included in the review.

Results

Results. The promising biomarkers of brain injury determined in the blood serum of newborns were detected: dipeptidyl peptidase 4, a number of cytokines, neuron-specific enolase (NSE), butylcarnitine, calcium-binding protein B S100 (S100B), F2-isoprostanes, nucleated erythrocytes, and some other biomarkers, the change in the level of which correlated with the severity of CNS tissue damage.

Conclusion

Conclusion. Blood-brain barrier dysfunction causes the appearance of highly specific proteins of neuronal and glial injury, in particular S100B and NSE, in blood serum, which can be determined as biomarkers. It is necessary to expand the evidence base and validation of using the mentioned biomarkers for subsequent implementation in clinical guidelines on managing patients with CNS tissue damage in the early postnatal period for timely diagnosis and correction of rehabilitation measures.

Новорожденныебиомаркерыголовной мозггипоксически-ишемическое повреждениецентральная нервная системаЦНСгематоэнцефалический барьерГЭБасфиксиядиагностикареабилитация

Newbornsbiomarkersbrainhypoxic-ischemic injurycentral nervous systemCNSblood-brain barrierBBBasphyxiadiagnosticsrehabilitation

Авторы заявляют об отсутствии финансовой поддержки

The authors declare no funding

References1

Cao Z., Lin H., Gao F., et al. Microstructural alterations in projection and association fibers in neonatal hypoxia-ischemia. J Magn Reson Imaging. 2023; 57 (4): 1131–42. https://doi.org/10.1002/jmri.28366.

Stoke R., Schreiber V., Hocking K., et al. Perinatal antecedents of moderate and severe neonatal hypoxic ischaemic encephalopathy: an Australian birth cohort study. Aust N Z J Obstet Gynaecol. 2023; 63 (3): 409–17. https://doi.org/10.1111/ajo.13665.

Ravichandran L., Allen V.M., Allen A.C., et al. Incidence, intrapartum risk factors, and prognosis of neonatal hypoxic-ischemic encephalopathy among infants born at 35 weeks gestation or more. J Obstet Gynaecol Can. 2020; 42 (12): 1489–97. https://doi.org/10.1016/j.jogc.2020.04.020.

Perrone S., Santacroce A., Picardi A., Buonocore G. Fetal programming and early identification of newborns at high risk of free radical-mediated diseases. World J Clin Pediatr. 2016; 5 (2): 172–81. https://doi.org/10.5409/wjcp.v5.i2.172.

Perrone S., Grassi F., Caporilli C., et al. Brain damage in preterm and full-term neonates: serum biomarkers for the early diagnosis and intervention. Antioxidants. 2023; 12 (2): 309. https://doi.org/10.3390/antiox12020309.

Lembo C., Buonocore G., Perrone S. Oxidative stress in preterm newborns. Antioxidants. 2021; 10 (11): 1672. https://doi.org/10.3390/ antiox10111672.

Amoo M., Henry J., O’Halloran P.J., et al. S100B, GFAP, UCH-L1 and NSE as predictors of abnormalities on CT imaging following mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy. Neurosurg REV. 2022; 45 (2): 1171–93. https://doi.org/10.1007/s10143-021-01678-z.

Kadry H., Noorani B., Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020; 17 (1): 69. https://doi.org/10.1186/s12987-02000230-3.

Marchi N., Rasmussen P., Kapural M., et al. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci. 2003; 21 (3–4): 109–21.

Salmina A.B., Komleva Y.K., Malinovskaya N.A., et al. Blood-brain barrier breakdown in stress and neurodegeneration: biochemical mechanisms and new models for translational research. Biochemistry. 2021; 86 (6): 746–60. https://doi.org/10.1134/S0006297921060122.

Osipova E.D., Semyachkina-Glushkovskaya O.V., Morgun A.V., et al. Gliotransmitters and cytokines in the control of blood-brain barrier permeability. REV Neurosci. 2018; 29 (5): 567–91. https://doi.org/10.1515/revneuro-2017-0092.

PRISMA 2020 statement. URL: https://www.prisma-statement.org/ prisma-2020-statement (дата обращения 27.06.2023).

PRISMA 2020 statement. Available at: https://www.prismastatement.org/prisma-2020-statement (accessed 27.06.2023).

Volpe J.J. Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurol. 2009; 8 (1): 110–24. https://doi.org/10.1016/S1474-4422(08)70294-1.

Bauer C.M., Papadelis C. Alterations in the structural and functional connectivity of the visuomotor network of children with periventricular leukomalacia. Semin Pediatr Neurol. 2019; 31: 48–56. https://doi.org/10.1016/j.spen.2019.05.009.

Jimenez-Gomez A., Fisher K.S., Zhang K.X., et al. Longitudinal neurological analysis of moderate and severe pediatric cerebral visual impairment. Front Hum Neurosci. 2022; 16: 772353. https://doi.org/10.3389/fnhum.2022.772353.

Venkatakrishna S.S.B., Elsingergy M., Worede F., et al. Unequal cerebral magnetic resonance imaging changes in perinatal hypoxic ischemic injury of term neonates. J Comput Assist Tomogr. 2023; 47 (6): 913–8. https://doi.org/10.1097/RCT.0000000000001486.

Детский церебральный паралич (ДЦП). Клинические рекомендации. 2017. URL: https://rehabrus.ru/Docs/2017/06/KR_DPC.pdf (дата обращения 27.06.2023).

Cerebral palsy. Clinical guidelines. 2017. Available at: https://rehabrus.ru/Docs/2017/06/KR_DPC.pdf (in Russ.) (accessed 27.06.2023).

Spittle A.J., Morgan C., Olsen J.E., et al. Early diagnosis and treatment of cerebral palsy in children with a history of preterm birth. Clin Perinatol. 2018; 45 (3): 409–20. https://doi.org/10.1016/j.clp.2018.05.011.

Yıldız E.P., Ekici B., Tatlı B. Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. Expert REV Neurother. 2017; 17 (5): 449–59. https://doi.org/10.1080/14737175.2017.1259567.

Thoresen M., Tooley J., Liu X., et al. Time is brain: starting therapeutic hypothermia within three hours after birth improves motor outcome in asphyxiated newborns. Neonatology. 2013; 104 (3): 228–33. https://doi.org/10.1159/000353948.

Shankaran S., Laptook A.R., Ehrenkranz R.A., et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005; 353 (15): 1574–84. https://doi.org/10.1056/NEJMcps050929.

Azzopardi D.V., Strohm B., Edwards A.D., et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009; 361 (14): 1349–58. https://doi.org/10.1056/NEJMoa0900854.

Albrecht M., Zitta K., Groenendaal F., et al. Neuroprotective strategies following perinatal hypoxia-ischemia: taking aim at NOS. Free Radic Biol Med. 2019; 142: 123–31. https://doi.org/10.1016/j.00000000000freeradbiomed.2019.02.025.

Perrone S., Lembo C., Gironi F., et al. Erythropoietin as a neuroprotective drug for newborn infants: ten years after the first use. Antioxidants. 2022; 11 (4): 652. https://doi.org/10.3390/antiox11040652.

de Cerio F.G., Lara-Celador I., Alvarez A., Hilario E. Neuroprotective therapies after perinatal hypoxic-ischemic brain injury. Brain Sci. 2013; 3 (1): 191–214. https://doi.org/10.3390/brainsci3010191.

Lee J., Croen L.A., Backstrand K.H., et al. Maternal and infant characteristics associated with perinatal arterial stroke in the infant. JAMA. 2005; 293 (6): 723–9. https://doi.org/10.1001/jama.293.6.723.

Sarjare S., Nedunchelian M., Ravichandran S., et al. Role of advanced (magnetic resonance) neuroimaging and clinical outcomes in neonatal strokes: experience from tertiary care center. Neuroradiol J. 2023; 36 (3): 297–304. https://doi.org/10.1177/19714009221130488.

Ilves N., Pajusalu S., Kahre T., et al. High prevalence of collagenopathies in pretermand term-born children with periventricular venous hemorrhagic infarction. J Child Neurol. 2023; 38 (6–7): 373–88. https://doi.org/10.1177/08830738231186233.

Bernson-Leung M.E., Rivkin M.J. Stroke in neonates and children. Pediatr REV. 2016; 37 (11): 463–77. https://doi.org/10.1542/pir.20160002.

Natale F., De Curtis M., Bizzarri B., et al. Isolated auditory neuropathy at birth in congenital cytomegalovirus infection. Ital J Pediatr. 2020; 46 (1): 3. https://doi.org/10.1186/s13052-019-0767-y.

Zhong J., Kankanala S., Rajagopalan S. DPP4 inhibition: insights from the bench and recent clinical studies. Curr Opin Lipidol. 2016; 27 (5): 484–92. https://doi.org/10.1097/MOL.0000000000000340.

Röhnert P., Schmidt W., Emmerlich P., et al. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation. 2012; 9 (1): 44. https://doi.org/10.1186/17422094-9-44.

Yakovleva A.A., Zolotov N.N., Sokolov O.Y., et al. Dipeptidylpeptidase 4 (DPP4, CD26) activity in the blood serum of term and preterm neonates with cerebral ischemia. Neuropeptides. 2015; 52: 113–7. https://doi.org/10.1016/j.npep.2015.05.001.

Локшина Л.А. Протеиназы плазматической мембраны лимфоидных клеток и их биологические функции (обзорная статья). Биоорганическая химия. 1998; 24 (5): 323–31.

Lokshina L.A. Plasma membrane proteinases of lymphoid cells and their biological functions. Bioorganicheskaya khimiya / Russian Journal of Bioorganic Chemistry. 1998; 24 (5): 323–31 (in Russ.).

Malva J.O., Xapelli S., Baptista S., et al. Multifaces of neuropeptide Y in the brain – neuroprotection, neurogenesis and neuroinflammation. Neuropeptides. 2012; 46 (6): 299–308. https://doi.org/10.1016/j.npep.2012.09.001.

Iwai T., Sawabe T., Tanimitsu K., et al. Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents. J Neurosci Res. 2014; 92 (4): 446–54. https://doi.org/10.1002/jnr.23335.

Douglas-Escobar M., Weiss M.D. Biomarkers of hypoxic-ischemic encephalopathy in newborns. Front Neurol. 2012; 3: 144. https://doi.org/10.3389/fneur.2012.00144.

Kaur C., Rathnasamy G., Ling E.A. Roles of activated microglia in hypoxia induced neuroinflammation in the developing brain and the retina. J Neuroimmune Pharmacol. 2013; 8 (1): 66–78. https://doi.org/10.1007/s11481-012-9347-2.

Chiesa C., Pellegrini G., Panero A., et al. Umbilical cord interleukin-6 levels are elevated in term neonates with perinatal asphyxia. Eur J Clin INVest. 2003; 33 (4): 352–8. https://doi.org/10.1046/j.1365-2362. 2003.01136.x.

Chaparro-Huerta V., Flores-Soto M.E., Merin Sigala M.E., et al. Proinflammatory cytokines, enolase and S-100 as early biochemical indicators of hypoxic-ischemic encephalopathy following perinatal asphyxia in newborns. Pediatr Neonatol. 2017; 58 (1): 70–6. https://doi.org/10.1016/j.pedneo.2016.05.001.

Fotopoulos S., Pavlou K., Skouteli H., et al. Early markers of brain damage in premature low-birth-weight neonates who suffered from perinatal asphyxia and/or infection. Biol Neonate. 2001; 79 (3–4): 213–8. https://doi.org/10.1159/000047094.

Hanin A., Denis J.A., Frazzini V., et al. Neuron specific enolase, S100beta protein and progranulin as diagnostic biomarkers of status epilepticus. J Neurol. 2022; 269 (7): 3752–60. https://doi.org/10.1007/s00415-022-11004-2.

Hanin A., Demeret S., Denis J.A., et al. Serum neuron-specific enolase: a new tool for seizure risk monitoring after status epilepticus. Eur J Neurol. 2022; 29 (3): 883–9. https://doi.org/10.1111/ene.15154.

Celtik C., Acunaş B., Oner N., Pala O. Neuron-specific enolase as a marker of the severity and outcome of hypoxic ischemic encephalopathy. Brain DEV. 2004; 26 (6): 398–402. https://doi.org/10.1016/j.braindev.2003.12.007.

Giuseppe D., Sergio C., Pasqua B., et al. Perinatal asphyxia in preterm neonates leads to serum changes in protein S-100 and neuron specific enolase. Curr NEUROVASC Res. 2009; 6 (2): 110–6. https://doi.org/10.2174/156720209788185614.

López-Suárez O., Concheiro-Guisán A., Sánchez-Pintos P., et al. Acylcarnitine profile in neonatal hypoxic-ischemic encephalopathy: the value of butyrylcarnitine as a prognostic marker. Medicine. 2019; 98 (15): e15221. https://doi.org/10.1097/MD.0000000000015221.

Nagdyman N., Kömen W., Ko H.K., et al. Early biochemical indicators of hypoxic-ischemic encephalopathy after birth asphyxia. Pediatr Res. 2001; 49 (4): 502–6. https://doi.org/10.1203/00006450-20010400000011.

Willoughby K.A., Kleindienst A., Müller C., et al. S100B protein is released by in vitro trauma and reduces delayed neuronal injury. J Neurochem. 2004; 91 (6): 1284–91. https://doi.org/10.1111/j.1471-4159.2004.02812.x.

Michetti F., Corvino V., Geloso M.C., et al. The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. J Neurochem. 2012; 120 (5): 644–59. https://doi.org/10.1111/j.1471-4159.2011.07612.x.

Lam A.G., Koppal T., Akama K.T., et al. Mechanism of glial activation by S100B: involvement of the transcription factor NFkappaB. Neurobiol Aging. 2001; 22 (5): 765–72. https://doi.org/10.1016/s01974580(01)00233-0.

Gazzolo D., Marinoni E., Di Iorio R., et al. Measurement of urinary S100B protein concentrations for the early identification of brain damage in asphyxiated full-term infants. Arch Pediatr Adolesc Med. 2003; 157 (12): 1163–8. https://doi.org/10.1001/archpedi.157.12.1163.

Beharier O., Kahn J., Shusterman E., Sheiner E. S100B – a potential biomarker for early detection of neonatal brain damage following asphyxia. J Matern Fetal Neonatal Med. 2012; 25 (9): 1523–8. https://doi.org/10.3109/14767058.2012.664200.

Aisa M.C., Cappuccini B., Favilli A., et al. Biochemical and anthropometric parameters for the early recognition of the intrauterine growth restriction and preterm neonates at risk of impaired neurodevelopment. Int J Mol Sci. 2023; 24 (14): 11549. https://doi.org/10.3390/ijms241411549.

Gazzolo D., Bruschettini M., Lituania M., et al. Increased urinary S100B protein as an early indicator of intraventricular hemorrhage in preterm infants: correlation with the grade of hemorrhage. Clin Chem. 2001; 47 (10): 1836–8.

Tskitishvili E., Komoto Y., Temma-Asano K., et al. S100B protein expression in the amnion and amniotic fluid in pregnancies complicated by pre-eclampsia. Mol Hum Reprod. 2006; 12 (12): 755–61. https://doi.org/10.1093/molehr/gal083.

Gazzolo D., Marinoni E., Di Iorio R., et al. High maternal blood S100B concentrations in pregnancies complicated by intrauterine growth restriction and intraventricular hemorrhage. Clin Chem. 2006; 52 (5): 819–26. https://doi.org/10.1373/clinchem.2005.060665.

Milne G.L., Musiek E.S., Morrow J.D. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers. 2005; 10 (Suppl. 1): S10–23. https://doi.org/10.1080/13547500500216546.

Matthews M.A., Aschner J.L., Stark A.R., et al. Increasing F2-isoprostanes in the first month after birth predicts poor respiratory and neurodevelopmental outcomes in very preterm infants. J Perinatol. 2016; 36 (9): 779–83. https://doi.org/10.1038/jp.2016.74.

Coviello C., Perrone S., Buonocore G., et al. Oxidative stress biomarkers and early brain activity in extremely preterm infants: a prospective cohort study. Children. 2022; 9 (9): 1376. https://doi.org/10.3390/children9091376.

Coviello C., Tataranno M.L., Corsini I., et al. Isoprostanes as biomarker for patent ductus arteriosus in preterm infants. Front Pediatr. 2020; 8: 555. https://doi.org/10.3389/fped.2020.00555.

Green D.W., Hendon B., Mimouni F.B. Nucleated erythrocytes and intraventricular hemorrhage in preterm neonates. Pediatrics. 1995; 96 (3 Pt 1): 475–8.

Florio P., Perrone S., Luisi S., et al. Activin a plasma levels at birth: an index of fetal hypoxia in preterm newborn. Pediatr Res. 2003; 54 (5): 696–700. https://doi.org/10.1203/01.PDR.0000086905.71963.1D.

The authors declare that there are no conflicts of interest present.